The company has enrolled 10 patients, marking early momentum in evaluating a novel, non-invasive, drug-centered therapeutic approach to brain cancer treatment.
Funds to support first-in-human (FIH) clinical trial of the company’s proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas
SAB to provide meaningful guidance as the company begins a first-in-human (FIH) clinical trial of their proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas
Milestone arrives as the company closes a $14 million follow-on Series A financing round to expand the clinical program for high-grade gliomas, including glioblastomas, and pursue additional indications.
The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM)
The results from their first-in-human study demonstrated that median overall survival was doubled and progression-free survival improved 3-fold. The Company’s novel sonodynamic therapy platform selectively targets and destroys cancer cells in the brain while preserving healthy tissue.
“SDT’s ability to selectively induce immediate tumor cell death while sparing healthy brain tissue is unprecedented.”
Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma.